Selective iNOS inhibition for the treatment of sepsis-induced acute kidney injury

Nature Reviews Nephrology

Volumn 5, Issue 11, 2009, Pages 629-640

  Heemskerk, Suzanne ^a   Masereeuw, Rosalinde ^a   Russel, Frans G M ^a   Pickkers, Peter ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO 6 HYDROXY PYRIMIDINE; 7 CHLORO 3 IMINO 5 METHYL 2 AZABICYCLO[4.1.0]HEPTANE; AFELIMOMAB; ALKALINE PHOSPHATASE; AMINOGUANIDINE; ANTIBIOTIC AGENT; ANTISERUM; CANAVANINE; CENTOXIN; DEXAMETHASONE; ENDOTOXIN ANTIBODY; GLUCOCORTICOID; IMMUNOGLOBULIN G; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYL ISOTHIOUREA; METHYLENE BLUE; METHYLGUANIDINE; N [3 (AMINOMETHYL)BENZYL]ACETAMIDINE; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE SYNTHASE INHIBITOR; PEROXYNITRITE; PLACEBO; REACTIVE NITROGEN SPECIES; RECOMBINANT BACTERICIDAL PERMEABILITY INCREASING PROTEIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ACUTE DISEASE; BIOSYNTHESIS; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; ENDOTOXEMIA; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME METABOLISM; FLUID THERAPY; GRAM NEGATIVE SEPSIS; HUMAN; INCIDENCE; INFLAMMATION; KIDNEY BLOOD FLOW; KIDNEY INJURY; KIDNEY PROXIMAL TUBULE; LOW DRUG DOSE; MICROCIRCULATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SURVIVAL; UPREGULATION;

ANIMALS; ENZYME INHIBITORS; HUMANS; KIDNEY FAILURE, ACUTE; NITRIC OXIDE SYNTHASE TYPE II; SEPSIS;

EID: 70350575360     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.155     Document Type: Review

References (176)

1. Teres, D., Rapoport, J., Lemeshow, S., Kim, S. & Akhras, K. effects of severity of illness on resource use by survivors and nonsurvivors of severe sepsis at intensive care unit admission. Crit. Care Med. 30, 2413-2419 (2002).
2. Vincent, J. L. et al. Sepsis in european intensive care units: results of the SOAP study. Crit. Care Med. 34, 344-353 (2006).
3. Silva, E. et al. Brazilian Sepsis epidemiological Study (BASeS). Crit. Care 8, R251-R260 (2004).
4. Nguyen, H. B. et al. Severe sepsis and septic shock: review of the literature and emergency department management guidelines. Ann. Emerg. Med. 48, 28-54 (2006).
5. Chertow, G. M. et al. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int. 70, 1120-1126 (2006).
6. Ronco, C., Kellum, J. A., Bellomo, R. & House, A. A. Potential interventions in sepsisrelated acute kidney injury. Clin. J. Am. Soc. Nephrol. 3, 531-544 (2008).
7. Bagshaw, S. M. et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin. J. Am. Soc. Nephrol. 2, 431-439 (2007).
8. Bellomo, R., Ronco, C., Kellum, J. A., Mehta, R. L. & Palevsky, P. Acute renal failure- definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit. Care 8, R204-R212 (2004).
9. Mehta, R. L. et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care 11, R31 (2007).
10. Lopes, J. A. et al. Acute kidney injury in patients with sepsis: a contemporary analysis. Int. J. Infect. Dis. 13, 176-181 (2009).
11. Bagshaw, S. M. et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 35, 871-881 (2009).
12. Neveu, H., Kleinknecht, D., Brivet, F., Loirat, P. & Landais, P. Prognostic factors in acute renal failure due to sepsis. Results of a prospective multicentre study. The French Study Group on Acute Renal Failure. Nephrol. Dial. Transplant. 11, 293-299 (1996).
13. wan, L. et al. Pathophysiology of septic acute kidney injury: what do we really know? Crit. Care Med. 36, S198-S203 (2008).
14. Lopes, J. A. et al. Acute renal failure in patients with sepsis. Crit. Care 11, 411 (2007).
15. Opal, S. M. et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPSbinding protein in patients with severe sepsis and septic shock. J. Infect. Dis. 180, 1584-1589 (1999).
16. Marshall, J. C. Lipopolysaccharide: an endotoxin or an exogenous hormone? Clin. Infect. Dis. 41 (Suppl. 7), S470-S480 (2005).
17. Braude, A. I., Carey, F. J. & Zalesky, M. Studies with radioactive endotoxin. II. Correlation of physiologic effects with distribution of radioactivity in rabbits injected with radioactive sodium chromate. J. Clin. Invest. 34, 858-866 (1955).
18. De Haas, C. J., Van Leeuwen, H. J., Verhoef, J., Van Kessel, K. P. & van Strijp, J. A. Analysis of lipopolysaccharide (LPS)-binding characteristics of serum components using gel filtration of FITC-labeled LPS. J. Immunol. Methods 242, 79-89 (2000).
19. Triantafilou, M. & Triantafilou, K. Lipopolysaccharide recognition: CD14, TLRs and the LPS-activation cluster. Trends Immunol. 23, 301-304 (2002).
20. Chowdhury, P., Sacks, S. H. & Sheerin, N. S. Tolllike receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products. Clin. Exp. Immunol. 145, 346-356 (2006).
21. Lopez-Bojorquez, L. N., Dehesa, A. Z. & Reyes-Teran, G. Molecular mechanisms involved in the pathogenesis of septic shock. Arch. Med. Res. 35, 465-479 (2004).
22. Dear, J. W. et al. Sepsis-induced organ failure is mediated by different pathways in the kidney and liver: acute renal failure is dependent on MyD88 but not renal cell apoptosis. Kidney Int. 69, 832-836 (2006).
23. Cohen, J. The immunopathogenesis of sepsis. Nature 420, 885-891 (2002).
24. Al-Lamki, R. S. et al. expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab. Invest. 81, 1503-1515 (2001).
25. Thiemermann, C. Nitric oxide and septic shock. Gen. Pharmacol. 29, 159-166 (1997). (Pubitemid 27312364)
26. Schrier, R. W. & Wang, W. Acute renal failure and sepsis. N. Engl. J. Med. 351, 159-169 (2004).
27. Knotek, M. et al. endotoxemic renal failure in mice: role of tumor necrosis factor independent of inducible nitric oxide synthase. Kidney Int. 59, 2243-2249 (2001).
28. Millar, C. G. & Thiemermann, C. Intrarenal haemodynamics and renal dysfunction in endotoxaemia: effects of nitric oxide synthase inhibition. Br. J. Pharmacol. 121, 1824-1830 (1997).
29. Chvojka, J. et al. Renal haemodynamic, microcirculatory, metabolic and histopathological responses to peritonitis-induced septic shock in pigs. Crit. Care 12, R164 (2008).
30. Johannes, T. et al. Low-dose dexamethasonesupplemented fluid resuscitation reverses endotoxin-induced acute renal failure and prevents cortical microvascular hypoxia. Shock 31, 521-528 (2009).
31. Chawla, L. S. et al. elevated plasma concentrations of IL-6 and elevated APACHe II score predict acute kidney injury in patients with severe sepsis. Clin. J. Am. Soc. Nephrol. 2, 22-30 (2007).
32. Traylor, L. A. & Mayeux, P. R. Nitric oxide generation mediates lipid-A-induced oxidant injury in renal proximal tubules. Arch. Biochem. Biophys. 338, 129-135 (1997).
33. Furchgott, R. F. & Zawadzki, J. V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376 (1980).
34. Beckman, J. S. & Koppenol, w. H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol. 271, C1424-C1437 (1996).
35. Lundberg, J. O. & weitzberg, e. NO generation from nitrite and its role in vascular control. Arterioscler. Thromb. Vasc. Biol. 25, 915-922 (2005).
36. Bultinck, J., Sips, P., Vakaet, L., Brouckaert, P. & Cauwels, A. Systemic NO production during (septic) shock depends on parenchymal and not on hematopoietic cells: in vivo iNOS expression pattern in (septic) shock. FASEB J. 20, 2363-2365 (2006).
37. Wang, W. et al. endotoxemia-related acute kidney injury in transgenic mice with endothelial overexpression of GTP cyclohydrolase-1. Am. J. Physiol. Renal Physiol. 294, F571-F576 (2008).
38. Ortiz, P. A. & Garvin, J. L. Cardiovascular and renal control in NOS-deficient mouse models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R628-R638 (2003).
39. Ahn, K. Y., Mohaupt, M. G., Madsen, K. M. & Kone, B. C. In situ hybridization localization of mRNA encoding inducible nitric oxide synthase in rat kidney. Am. J. Physiol. 267, F748-F757 (1994).
40. Markewitz, B. A., Michael, J. R. & Kohan, D. E. Cytokine-induced expression of a nitric oxide synthase in rat renal tubule cells. J. Clin. Invest. 91, 2138-2143 (1993).
41. Kone, B. C. & Baylis, C. Biosynthesis and homeostatic roles of nitric oxide in the normal kidney. Am. J. Physiol. 272, F561-F578 (1997).
42. Heemskerk, S. et al. Up-regulation of renal iNOS during human endotoxemia and sepsis is associated with proximal tubule injury. Clin. J. Am. Soc. Nephrol. 1, 853-862 (2006).
43. Heemskerk, S. et al. Alkaline phosphatase treatment improves renal function in severe sepsis or septic shock patients. Crit. Care Med. 37, 417e1-423e1 (2009).
44. Vallance, P. & Leiper, J. Blocking NO synthesis: how, where and why? Nat. Rev. Drug Discov. 1, 939-950 (2002).
45. Delles, C. et al. The role of nitric oxide in the regulation of glomerular haemodynamics in humans. Nephrol. Dial. Transplant. 19, 1392-1397 (2004).
46. Brown, R., Ollerstam, A. & Persson, A. E. Neuronal nitric oxide synthase inhibition sensitizes the tubuloglomerular feedback mechanism after volume expansion. Kidney Int. 65, 1349-1356 (2004).
47. Hu, L. & Manning, R. D. Jr. Role of nitric oxide in regulation of long-term pressure-natriuresis relationship in Dahl rats. Am. J. Physiol. 268, H2375-H2383 (1995).
48. Majid, D. S., Wlliams, A. & Navar, L. G. Inhibition of nitric oxide synthesis attenuates pressureinduced natriuretic responses in anesthetized dogs. Am. J. Physiol. 264, F79-F87 (1993).
49. De Nicola, L., Blantz, R. C. & Gabbai, F. B. Nitric oxide and angiotensin II. Glomerular and tubular interaction in the rat. J. Clin. Invest. 89, 1248-1256 (1992).
50. Schwartz, D. et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J. Clin. Invest. 100, 439-448 (1997).
51. Chauhan, S. D. et al. Protection against lipopolysaccharide-induced endothelial dysfunction in resistance and conduit vasculature of iNOS knockout mice. FASEB J. 17, 773-775 (2003).
52. Schwartz, D. & Blantz, R. C. Nitric oxide, sepsis, and the kidney. Semin. Nephrol. 19, 272-276 (1999).
53. Cohen, R. I. et al. Renal effects of nitric oxide in endotoxemia. Am. J. Respir. Crit. Care Med. 164, 1890-1895 (2001).
54. Shultz, P. J. & Raij, L. endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J. Clin. Invest. 90, 1718-1725 (1992).
55. Szabo, C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett. 140-141, 105-112 (2003).
56. Harrois, A., Huet, O. & Duranteau, J. Alterations of mitochondrial function in sepsis and critical illness. Curr. Opin. Anaesthesiol. 22, 143-149 (2009).
57. Lancaster, J. R. Jr. Simulation of the diffusion and reaction of endogenously produced nitric oxide. Proc. Natl Acad. Sci. USA 91, 8137-8141 (1994).
58. Yu, L., Gengaro, P. e., Niederberger, M., Burke, T. J. & Schrier, R. w. Nitric oxide: a mediator in rat tubular hypoxia/reoxygenation injury. Proc. Natl Acad. Sci. USA 91, 1691-1695 (1994).
59. Ling, H. et al. effect of hypoxia on proximal tubules isolated from nitric oxide synthase knockout mice. Kidney Int. 53, 1642-1646 (1998).
60. Peresleni, T., Noiri, E., Bahou, W. F. & Goligorsky, M. S. Antisense oligodeoxynucleotides to inducible NO synthase rescue epithelial cells from oxidative stress injury. Am. J. Physiol. 270, F971-F977 (1996).
61. Greenacre, S. A. & Ischiropoulos, H. Tyrosine nitration: localisation, quantification, consequences for protein function and signal transduction. Free Radic. Res. 34, 541-581 (2001).
62. Wu, L., Gokden, N. & Mayeux, P. R. evidence for the role of reactive nitrogen species in polymicrobial sepsis-induced renal peritubular capillary dysfunction and tubular injury. J. Am. Soc. Nephrol. 18, 1807-1815 (2007).
63. Wu, Y. T., Chou, Y. C., Guo, w. Y., Yeh, T. C. & Hsieh, J. C. Classification of spatiotemporal hemodynamics from brain perfusion MR images using expectation-maximization estimation with finite mixture of multivariate Gaussian distributions. Magn. Reson. Med. 57, 181-191 (2007).
64. wolin, M. S., Ahmad, M. & Gupte, S. A. The sources of oxidative stress in the vessel wall. Kidney Int. 67, 1659-1661 (2005).
65. Molitoris, B. A. & Sutton, T. A. endothelial injury and dysfunction: role in the extension phase of acute renal failure. Kidney Int. 66, 496-499 (2004).
66. Yuan, H. T., Li, X. Z., Pitera, J. e., Long, D. A. & woolf, A. S. Peritubular capillary loss after mouse acute nephrotoxicity correlates with down-regulation of vascular endothelial growth factor-A and hypoxia-inducible factor-1á. Am. J. Pathol. 163, 2289-2301 (2003).
67. Tiwari, M. M., Brock, R. w., Megyesi, J. K., Kaushal, G. P. & Mayeux, P. R. Disruption of renal peritubular blood flow in lipopolysaccharide-induced renal failure: role of nitric oxide and caspases. Am. J. Physiol. Renal Physiol. 289, F1324-F1332 (2005).
68. Cuzzocrea, S. et al. A role for nitric oxidemediated peroxynitrite formation in a model of endotoxin-induced shock. J. Pharmacol. Exp. Ther. 319, 73-81 (2006).
69. Bian, K., Davis, K., Kuret, J., Binder, L. & Murad, F. Nitrotyrosine formation with endotoxin-induced kidney injury detected by immunohistochemistry. Am. J. Physiol. 277, F33-F40 (1999).
70. Heemskerk, S. et al. Nitric oxide differentially regulates renal ATP binding cassette transporters during endotoxemia. Pflugers Archiv. Eur. J. Physiol. 454, 321-334 (2007).
71. Zhang, C., walker, L. M. & Mayeux, P. R. Role of nitric oxide in lipopolysaccharide-induced oxidant stress in the rat kidney. Biochem. Pharmacol. 59, 203-209 (2000).
72. Fukuyama, N. et al. Clinical evidence of peroxynitrite formation in chronic renal failure patients with septic shock. Free Radic. Biol. Med. 22, 771-774 (1997).
73. Groeneveld, P. H., Kwappenberg, K. M., Langermans, J. A., Nibbering, P. H. & Curtis, L. Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. Intensive Care Med. 22, 1197-1202 (1996).
74. Evans, T., Carpenter, A., Kinderman, H. & Cohen, J. evidence of increased nitric oxide production in patients with the sepsis syndrome. Circ. Shock 41, 77-81 (1993).
75. Werra, I. D. et al. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit. Care Med. 25, 607-613 (1997).
76. Ochoa, J. B. et al. Nitrogen oxide levels in patients after trauma and during sepsis. Ann. Surg. 214, 621-626 (1991).
77. Wang, H. D., Lu, D. X. & Qi, R. B. Therapeutic strategies targeting the LPS signaling and cytokines. Pathophysiology 16, 291-296 (2009).
78. Ianaro, A., Tersigni, M. & D'Acquisto, F. New insight in LPS antagonist. Mini Rev. Med. Chem. 9, 306-317 (2009).
79. Lorente, J. A. & Marshall, J. C. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 24 (Suppl. 1), 107-119 (2005).
80. Radomski, M. w., Palmer, R. M. & Moncada, S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc. Natl Acad. Sci. USA 87, 10043-10047 (1990).
81. Tsao, C. M. et al. Low-dose dexamethasone ameliorates circulatory failure and renal dysfunction in conscious rats with endotoxemia. Shock 21, 484-491 (2004).
82. Miyaji, T. et al. ethyl pyruvate decreases sepsisinduced acute renal failure and multiple organ damage in aged mice. Kidney Int. 64, 1620-1631 (2003).
83. Chiao, C. w., Lee, S. S., wu, C. C. & Su, M. J. N-Allylsecoboldine as a novel agent prevents acute renal failure during endotoxemia. Eur. J. Pharmacol. 535, 291-300 (2006).
84. Liaw, W. J. et al. effects of a membranepermeable radical scavenger, Tempol, on intraperitoneal sepsis-induced organ injury in rats. Shock 23, 88-96 (2005).
85. Kadkhodaee, M. & Qasemi, A. Inhibition of inducible nitric oxide synthase reduces lipopolysaccharide-induced renal injury in the rat. Clin. Exp. Pharmacol. Physiol. 31, 842-846 (2004).
86. Rees, D. D., Palmer, R. M., Schulz, R., Hodson, H. F. & Moncada, S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. 101, 746-752 (1990). (Pubitemid 20357206)
87. Southan, G. J. & Szabo, C. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem. Pharmacol. 51, 383-394 (1996).
88. Thiemermann, C., Szabo, C., Mitchell, J. A. & Vane, J. R. Vascular hyporeactivity to vasoconstrictor agents and hemodynamic decompensation in hemorrhagic shock is mediated by nitric oxide. Proc. Natl Acad. Sci. USA 90, 267-271 (1993).
89. Bolton, W. K. et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am. J. Nephrol. 24, 32-40 (2004).
90. Ruetten, H., Southan, G. J., Abate, A. & Thiemermann, C. Attenuation of endotoxininduced multiple organ dysfunction by 1-amino-2-hydroxy-guanidine, a potent inhibitor of inducible nitric oxide synthase. Br. J. Pharmacol. 118, 261-270 (1996).
91. Szabo, C. et al. Mercaptoethylguanidine and guanidine inhibitors of nitric-oxide synthase react with peroxynitrite and protect against peroxynitrite-induced oxidative damage. J. Biol. Chem. 272, 9030-9036 (1997).
92. Boer, R. et al. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol. Pharmacol. 58, 1026-1034 (2000).
93. Garvey, E. P. et al. Potent and selective inhibition of human nitric oxide synthases. Inhibition by nonamino acid isothioureas. J. Biol. Chem. 269, 26669-26676 (1994).
94. Blasko, E. et al. Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J. Biol. Chem. 277, 295-302 (2002).
95. Matejovic, M. et al. Selective inducible nitric oxide synthase inhibition during long-term hyperdynamic porcine bacteremia. Shock 21, 458-465 (2004).
96. Asakura, H. et al. Selective inducible nitric oxide synthase inhibition attenuates organ dysfunction and elevated endothelin levels in LPS-induced DIC model rats. J. Thromb. Haemost. 3, 1050-1055 (2005).
97. Wray, G. M., Millar, C. G., Hinds, C. J. & Thiemermann, C. Selective inhibition of the activity of inducible nitric oxide synthase prevents the circulatory failure, but not the organ injury/ dysfunction, caused by endotoxin. Shock 9, 329-335 (1998).
98. Liaudet, L., Fishman, D., Markert, M., Perret, C. & Feihl, F. l-Canavanine improves organ function and tissue adenosine triphosphate levels in rodent endotoxemia. Am. J. Respir. Crit. Care Med. 155, 1643-1648 (1997).
99. Marzocco, S. et al. effect of methylguanidine in a model of septic shock induced by LPS. Free Radic. Res. 38, 1143-1153 (2004).
100. Russell, J. A. Management of sepsis. N. Engl. J. Med. 355, 1699-1713 (2006).
101. De Vriese, A. S. Prevention and treatment of acute renal failure in sepsis. J. Am. Soc. Nephrol. 14, 792-805 (2003).
102. Rivers, E. et al. early goal-directed therapy in the treatment of severe sepsis and septic shock. N. Engl. J. Med. 345, 1368-1377 (2001).
103. Van Den Berghe, G. et al. Intensive insulin therapy in the critically ill patients. N. Engl. J. Med. 345, 1359-1367 (2001).
104. Schetz, M., Vanhorebeek, I., Wouters, P. J., Wilmer, A. & Van Den Berghe, G. Tight blood glucose control is renoprotective in critically ill patients. J. Am. Soc. Nephrol. 19, 571-578 (2008).
105. Griesdale, D. E. et al. Intensive insulin therapy and mortality among critically ill patients: a metaanalysis including NICe-SUGAR study data. CMAJ 180, 821-827 (2009).
106. [No authors listed] Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. The Acute Respiratory Distress Syndrome Network. N. Engl. J. Med. 342, 1301-1308 (2000).
107. Bernard, G. R. et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N. Engl. J. Med. 336, 912-918 (1997).
108. Keh, D. & Sprung, C. L. Use of corticosteroid therapy in patients with sepsis and septic shock: an evidence-based review. Crit. Care Med. 32, S527-S533 (2004).
109. Annane, D. Glucocorticoids in the treatment of severe sepsis and septic shock. Curr. Opin. Crit. Care 11, 449-453 (2005).
110. Sprung, C. L. et al. Hydrocortisone therapy for patients with septic shock. N. Engl. J. Med. 358, 111-124 (2008).
111. Warren, H. S., Suffredini, A. F., Eichacker, P. Q. & Munford, R. S. Risks and benefits of activated protein C treatment for severe sepsis. N. Engl. J. Med. 347, 1027-1030 (2002).
112. Bernard, G. R. et al. efficacy and safety of recombinant human activated protein C for severe sepsis. N. Engl. J. Med. 344, 699-709 (2001).
113. woodward, B. & Cartwright, M. Safety of drotrecogin alfa (activated) in severe sepsis: data from adult clinical trials and observational studies. J. Crit. Care doi:10.1016/ j.jcrc.2008.11.011
114. Martich, G. D., Boujoukos, A. J. & Suffredini, A. Response of man to endotoxin. Immunobiology 187, 403-416 (1993).
115. Taveira da Silva, A. M. et al. Brief report: shock and multiple-organ dysfunction after selfadministration of Salmonella endotoxin. N. Engl. J. Med. 328, 1457-1460 (1993).
116. Baumgartner, J. D. et al. Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPSinduced tumor necrosis factor á and interleukin 6. Comparison of O-side-chainspecific antibodies with core LPS antibodies. J. Exp. Med. 171, 889-896 (1990).
117. Bone, R. C. et al. A second large controlled clinical study of e5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The e5 Sepsis Study Group. Crit. Care Med. 23, 994-1006 (1995).
118. willatts, S. M., Radford, S. & Leitermann, M. effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebocontrolled, double-blind trial. Crit. Care Med. 23, 1033-1039 (1995).
119. Ziegler, E. J. et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N. Engl. J. Med. 324, 429-436 (1991).
120. Angus, D. C. et al. e5 murine monoclonal antiendotoxin antibody in Gram-negative sepsis: a randomized controlled trial. e5 Study Investigators. JAMA 283, 1723-1730 (2000).
121. warren, H. S. et al. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177, 89-97 (1993).
122. Gustafson, G. L. & Rhodes, M. J. A rationale for the prophylactic use of monophosphoryl lipid A in sepsis and septic shock. Biochem. Biophys. Res. Commun. 182, 269-275 (1992).
123. Poelstra, K., Bakker, W. W., Klok, P. A., Hardonk, M. J. & Meijer, D. K. A physiologic function for alkaline phosphatase: endotoxin detoxification. Lab. Invest. 76, 319-327 (1997). (Pubitemid 27157340)
124. Dinarello, C. A. Proinflammatory and antiinflammatory cytokines as mediators in the pathogenesis of septic shock. Chest 112, 321S-329S (1997).
125. Cavaillon, J. M., Adib-Conquy, M., Fitting, C., Adrie, C. & Payen, D. Cytokine cascade in sepsis. Scand. J. Infect. Dis. 35, 535-544 (2003).
126. Cunningham, P. N., Wang, Y., Guo, R., He, G. & Quigg, R. J. Role of Toll-like receptor 4 in endotoxin-induced acute renal failure. J. Immunol. 172, 2629-2635 (2004).
127. Fiedler, V. B. et al. Monoclonal antibody to tumor necrosis factor-á prevents lethal endotoxin sepsis in adult rhesus monkeys. J. Lab. Clin. Med. 120, 574-588 (1992).
128. Opal, S. M. et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebocontrolled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 25, 1115-1124 (1997).
129. Reinhart, K. & Karzai, W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 29, S121-S125 (2001).
130. Abraham, E. et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASePT II Study Group. Lancet 351, 929-933 (1998).
131. Cohen, J. & Carlet, J. INTeRSePT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-á in patients with sepsis. International Sepsis Trial Study Group. Crit. Care Med. 24, 1431-1440 (1996).
132. Angelo, D. J. Nitric oxide scavengers in the treatment of shock associated with systemic inflammatory response syndrome. Expert Opin. Pharmacother. 1, 19-29 (1999).
133. Yamada, M. et al. Discovery of novel and potent small-molecule inhibitors of NO and cytokine production as antisepsis agents: synthesis and biological activity of alkyl 6-(N-substituted sulfamoyl)cyclohex-1-ene-1-carboxylate. J. Med. Chem. 48, 7457-7467 (2005).
134. Kinasewitz, G. T. et al. Multicenter, randomized, placebo-controlled study of the nitric oxide scavenger pyridoxalated hemoglobin polyoxyethylene in distributive shock. Crit. Care Med. 36, 1999-2007 (2008).
135. Zacharowski, K. et al. The selective guanylate cyclase inhibitor ODQ reduces multiple organ injury in rodent models of Gram-positive and Gram-negative shock. Crit. Care Med. 29, 1599-1608 (2001).
136. Iwamoto, J., Yoshinaga, M., Yang, S. P., Krasney, e. & Krasney, J. Methylene blue inhibits hypoxic cerebral vasodilation in awake sheep. J. Appl. Physiol. 73, 2226-2232 (1992).
137. Mayer, B., Brunner, F. & Schmidt, K. Inhibition of nitric oxide synthesis by methylene blue. Biochem. Pharmacol. 45, 367-374 (1993).
138. Marczin, N., Ryan, U. S. & Catravas, J. D. Methylene blue inhibits nitrovasodilator- and endothelium-derived relaxing factor-induced cyclic GMP accumulation in cultured pulmonary arterial smooth muscle cells via generation of superoxide anion. J. Pharmacol. Exp. Ther. 263, 170-179 (1992).
139. Heemskerk, S. et al. Short-term beneficial effects of methylene blue on kidney damage in septic shock patients. Intensive Care Med. 34, 350-354 (2008).
140. Vallance, P., Leone, A., Calver, A., Collier, J. & Moncada, S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339, 572-575 (1992).
141. Nijveldt, R. J. et al. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol. Dial. Transplant. 18, 2542-2550 (2003).
142. Onozato, M. L. et al. expression of NG,NGdimethylarginine dimethylaminohydrolase and protein arginine, N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes 57, 172-180 (2008).
143. O'Dwyer, M. J. et al. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit. Care 10, R139 (2006).
144. Dijkhorst-Oei, L. T. & Koomans, H. A. effects of a nitric oxide synthesis inhibitor on renal sodium handling and diluting capacity in humans. Nephrol. Dial. Transplant. 13, 587-593 (1998).
145. Haynes, W. G. et al. Physiological role of nitric oxide in regulation of renal function in humans. Am. J. Physiol. 272, F364-F371 (1997).
146. Lopez, A. et al. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 32, 21-30 (2004).
147. Petros, A. et al. effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28, 34-39 (1994).
148. Schilling, J., Cakmakci, M., Battig, U. & Geroulanos, S. A new approach in the treatment of hypotension in human septic shock by NG-monomethyl-l-arginine, an inhibitor of the nitric oxide synthetase. Intensive Care Med. 19, 227-231 (1993).
149. Ou, P. & Wolff, S. P. Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem. Pharmacol. 46, 1139-1144 (1993).
150. Beehler, C. J. et al. Toxic effects of dimethylthiourea in rats. J. Lab. Clin. Med. 123, 73-80 (1994).
151. Qi, S. et al. effect of a novel inducible nitric oxide synthase inhibitor, FR260330, in prevention of renal ischemia/reperfusion injury in vervet monkeys. Transplantation 81, 627-631 (2006).
152. Chatterjee, P. K. et al. Gw274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 63, 853-865 (2003).
153. Le, B. B. et al. Discovery of a series of aminopiperidines as novel iNOS inhibitors. Bioorg. Med. Chem. Lett. 18, 336-343 (2008).
154. Thiemermann, C., Ruetten, H., Wu, C. C. & Vane, J. R. The multiple organ dysfunction syndrome caused by endotoxin in the rat: attenuation of liver dysfunction by inhibitors of nitric oxide synthase. Br. J. Pharmacol. 116, 2845-2851 (1995).
155. Gero, D. & Szabo, C. Poly(ADP-ribose) polymerase: a new therapeutic target? Curr. Opin. Anaesthesiol. 21, 111-121 (2008).
156. Van De Water, F. M. et al. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab. Dispos. 34, 1393-1397 (2006).
157. Schramm, L. et al. endotoxin-induced acute renal failure in rats: effects of l-arginine and nitric oxide synthase inhibition on renal function. J. Nephrol. 18, 374-381 (2005).
158. Hinder, F. et al. Nitric oxide synthase inhibition during experimental sepsis improves renal excretory function in the presence of chronically increased atrial natriuretic peptide. Crit. Care Med. 24, 131-136 (1996).
159. Mitaka, C. et al. S-Methylisothiourea sulfate improves renal, but not hepatic dysfunction in canine endotoxic shock model. Intensive Care Med. 26, 117-124 (2000).
160. Rosselet, A. et al. Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am. J. Respir. Crit. Care Med. 157, 162-170 (1998).
161. Szabo, C., Southan, G. J. & Thiemermann, C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc. Natl Acad. Sci. USA 91, 12472-12476 (1994).
162. Levy, B. et al. Comparative effects of vasopressin, norepinephrine, and l-canavanine, a selective inhibitor of inducible nitric oxide synthase, in endotoxic shock. Am. J. Physiol. Heart Circ. Physiol. 287, H209-H215 (2004).
163. Mitaka, C., Hirata, Y., Yokoyama, K., Makita, K. & Imai, T. A selective inhibitor for inducible nitric oxide synthase improves hypotension and lactic acidosis in canine endotoxic shock. Crit. Care Med. 29, 2156-2161 (2001).
164. Wu, C. C., Ruetten, H. & Thiemermann, C. Comparison of the effects of aminoguanidine and Nù-nitro-l-arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur. J. Pharmacol. 300, 99-104 (1996).
165. Wang, L., Fan, X. M. & Tang, H. X. effects of aminoguanidine in different dosages on renal function in endotoxin induced rabbits shock model [Chinese]. Zhonghua Er Ke Za Zhi 42, 206-209 (2004).
166. Ziegler, E. J. et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N. Engl. J. Med. 307, 1225-1230 (1982).
167. Calandra, T., Glauser, M. P., Schellekens, J. & Verhoef, J. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind, randomized trial. J. Infect. Dis. 158, 312-319 (1988).
168. Greenman, R. L. et al. A controlled clinical trial of e5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266, 1097-1102 (1991).
169. McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M. & Smith, C. R. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHeSS Trial Study Group. Ann. Intern. Med. 121, 1-5 (1994).
170. Levin, M. et al. Recombinant bactericidal/ permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Lancet 356, 961-967 (2000).
171. Werdan, K. et al. Score-based immunoglobulin G therapy of patients with sepsis: the SBITS study. Crit. Care Med. 35, 2693-2701 (2007).
172. Abraham, E. et al. efficacy and safety of monoclonal antibody to human tumor necrosis factor á in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-á MAb Sepsis Study Group. JAMA 273, 934-941 (1995).
173. Panacek, E. A. et al. efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab')2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit. Care Med. 32, 2173-2182 (2004).
174. Fisher, C. J. Jr et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1Ra Sepsis Syndrome Study Group. JAMA 271, 1836-1843 (1994).
175. Kirov, M. Y. et al. Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit. Care Med. 29, 1860-1867 (2001).
176. Andresen, M. et al. Use of methylene blue in patients with refractory septic shock: impact on hemodynamics and gas exchange. J. Crit. Care 13, 164-168 (1998).